Page last updated: 2024-12-11
eleutherobin
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
eleutherobin: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
| ID Source | ID |
|---|---|
| PubMed CID | 6918335 |
| CHEMBL ID | 504387 |
| SCHEMBL ID | 12015046 |
| MeSH ID | M0284269 |
Synonyms (15)
| Synonym |
|---|
| lew3mbq5wm , |
| unii-lew3mbq5wm |
| 174545-76-7 |
| eleutherobin |
| CHEMBL504387 |
| XOPYFXBZMVTEJF-PDACKIITSA-N |
| SCHEMBL12015046 |
| DTXSID20893496 |
| Q15410946 |
| [(1s,2s,4r,8r,9s,10z,12r)-11-[[(2r,3s,4r,5r)-3-acetyloxy-4,5-dihydroxyoxan-2-yl]oxymethyl]-12-methoxy-1,5-dimethyl-8-propan-2-yl-15-oxatricyclo[10.2.1.04,9]pentadeca-5,10,13-trien-2-yl] (e)-3-(1-methylimidazol-4-yl)prop-2-enoate |
| HY-149027 |
| CS-0566028 |
| beta-d-arabinopyranoside, [3,4,4a,7,10,11,12,12a-octahydro-7-methoxy-1,10-dimethyl-4-(1-methylethyl)-11-[[3-(1-methyl-1h-imidazol-4-yl)-1-oxo-2-propenyl]oxy]-7,10-epoxybenzocyclodecen-6-yl]methyl, 2-acetate, [4r-[4r*,4as*,5z,7r*,10s*,11s*(e),12ar*]]- |
| eleutherobin [mi] |
| beta-d-arabinopyranoside, [(4r,4as,5z,7r,10s,11s,12ar)-3,4,4a,7,10,11,12,12a-octahydro-7-methoxy-1,10-dimethyl-4-(1-methylethyl)-11-[[(2e)-3-(1-methyl-1h-imidazol-4-yl)-1-oxo-2-propen-1-yl]oxy]-7,10-epoxybenzocyclodecen-6-yl]methyl, 2-acetate |
Research Excerpts
Overview
Eleutherobin is a novel natural product isolated from a marine soft coral that is extremely potent for inducing tubulin polymerization in vitro. It is cytotoxic for cancer cells with an IC50 similar to that of paclitaxel.
| Excerpt | Reference | Relevance |
|---|---|---|
| "Eleutherobin is a novel natural product isolated from a marine soft coral that is extremely potent for inducing tubulin polymerization in vitro and is cytotoxic for cancer cells with an IC50 similar to that of paclitaxel. " | ( Eleutherobin, a novel cytotoxic agent that induces tubulin polymerization, is similar to paclitaxel (Taxol). Carboni, JM; Casazza, AM; Cornell, LA; Fairchild, CR; Fenical, W; Jensen, PR; Lindel, T; Long, BH; Wasserman, AJ, 1998) | 3.19 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Bioassays (4)
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID355718 | Cytotoxicity against human HeLa cells | 2003 | Journal of natural products, Apr, Volume: 66, Issue:4 | (Z)-sarcodictyin A, a new highly cytotoxic diterpenoid from the soft coral Bellonella albiflora. |
| AID1404367 | Cytotoxicity against human CD133/CD44 positive PPT2 cells assessed as cell death at 0.01 to 10 uM after 72 hrs by MTT assay | 2018 | Journal of natural products, 03-23, Volume: 81, Issue:3 | Quest for Efficacious Next-Generation Taxoid Anticancer Agents and Their Tumor-Targeted Delivery. |
| AID628149 | Antimitotic activity in human MCF7 cells assessed as mitotic arrest after 16 to 20 hrs by ELISA method | 2011 | Bioorganic & medicinal chemistry, Nov-15, Volume: 19, Issue:22 | Marine diterpene glycosides. |
| AID1404361 | Cytotoxicity against human CD133/CD44 positive PC3MM2 cells assessed as cell death at 0.01 to 10 uM after 72 hrs by MTT assay | 2018 | Journal of natural products, 03-23, Volume: 81, Issue:3 | Quest for Efficacious Next-Generation Taxoid Anticancer Agents and Their Tumor-Targeted Delivery. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
Research
Studies (26)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 5 (19.23) | 18.2507 |
| 2000's | 17 (65.38) | 29.6817 |
| 2010's | 4 (15.38) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
Market Indicators
Research Demand Index: 27.57
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (27.57) All Compounds (24.57) |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 6 (23.08%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 20 (76.92%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||